Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05503550
  4. Details
NCT05503550 Clinical Trial

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma Clinical Trial

Official title:
Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: No longer available

Administrative data
NCT number NCT05503550
Other study ID # CR109169
Secondary ID 64407564MMY4002
Status No longer available
Phase
First received
Last updated

Study information
Verified date January 2024
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Recruitment information / eligibility
Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Talquetamab
Talquetamab will be administered subcutaneously (SC).

Locations
Country Name City State
Belgium DUMMY Dummy
Iceland DUMMY Dummy
Portugal DUMMY Dummy
Slovenia DUMMY Dummy

Sponsors (1)
Lead Sponsor Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

Belgium,  Iceland,  Portugal,  Slovenia, 

See also
  Status Clinical Trial Phase
Terminated NCT03837509 - INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05519085 - A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 3
Active, not recruiting NCT02099539 - QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00545519 - A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Phase 1
Recruiting NCT05052970 - Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM Phase 1
Completed NCT03464916 - Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Phase 1
Recruiting NCT05455320 - A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment Phase 3
Withdrawn NCT05408026 - Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Phase 1/Phase 2
Active, not recruiting NCT04684108 - SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies Phase 1
Recruiting NCT05652335 - A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis Phase 1
Completed NCT03859427 - A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Phase 3
Not yet recruiting NCT06375044 - Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01866293 - Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Phase 1/Phase 2
Completed NCT01058434 - Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation Phase 2
Recruiting NCT04735575 - A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma Phase 1/Phase 2
Not yet recruiting NCT06298266 - To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma Early Phase 1
Recruiting NCT05572515 - A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Phase 3
Active, not recruiting NCT04798586 - MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma Phase 1
Terminated NCT02075021 - Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00478777 - A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Phase 3